Poor Solubility as a Program-Level Risk: How to Make Better Formulation Decisions

Poor solubility can create uncertainty across formulation strategy, CMC development, clinical interpretation, and future manufacturing plans. 

Poor solubility is one of the most common challenges in pharmaceutical development, yet the greatest risk often lies not in the molecule itself, but in making formulation decisions without sufficient evidence. 

This whitepaper explores how development teams can avoid costly reformulation, unnecessary complexity, and delays by preserving formulation options until human pharmacokinetic (PK) data support a clear path forward. 

Download our latest whitepaper to read what our experts suggest on how to reduce risk, preserve development flexibility, and select the right formulation pathway with confidence.